Business ❯Pharmaceuticals ❯Drug Development

Clinical Trials

Weight Loss Drugs FDA Approval Eli Lilly Schizophrenia Treatments Obesity Drugs Combination Therapy CagriSema Gilead Sciences Phase I Trial Phase II Trial Weight Loss Treatments Obesity Treatments Liver Therapies Synthetic Psilocybin

GSK Acquires Experimental Liver Drug Efimosfermin for $1.2 Billion Upfront

The deal, which could reach $2 billion with milestones, positions GSK to target unmet needs in liver disease with a planned 2029 launch.

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

FDA to Decide on First Twice-Yearly HIV Prevention Shot by June

Novo Nordisk Shares Plunge After Weight-Loss Drug Trial Falls Short

AbbVie Stock Plummets After Schizophrenia Drug Trials Fail

FDA Approves Vyalev for Advanced Parkinson's Disease Treatment

FDA Expands Recall of Diamond Shruumz Mushroom Chocolates